Boldly Attacking Alzheimer’s From Every Angle
Dear Friends,

When we founded the Alzheimer’s Drug Discovery Foundation (ADDF) 25 years ago in honor of our mother, Estée Lauder, there was little hope on the horizon for Alzheimer’s disease. But now, more than ever before, hope is here.

Along with our Co-Founder and Chief Science Officer Dr. Howard Fillit, we have made it our mission, through venture philanthropy, to leave no stone unturned, pushing research boundaries and lending support to ideas that may otherwise have been overlooked. And we are seeing tremendous progress as a result.

Many novel ideas for therapeutics we funded in early stages are progressing through clinical trials, making their way toward patients. We have helped to accelerate the development of new biomarkers to diagnose the disease earlier than ever, and to direct resources toward prevention research to delay the onset and progression of disease.

It is an honor that award-winning scientists like recent Goodes Prize recipients Dr. Rhoda Au, Dr. Miranda Orr, and Dr. Jeff Cummings and entrepreneurs like Bill Gates, Jeff Bezos, the Dolby family, and the Foundation for a Better World continue to work alongside us in advancing our mission to transform the way the world understands Alzheimer’s.

We are confident that these strong partnerships, the loyalty of our donors, and the cutting-edge science we support will eradicate this disease for future generations, finishing the work we started almost three decades ago.

And so, we thank you for your commitment to the search for new and effective Alzheimer’s therapies.

With our gratitude,

Leonard A. Lauder  
Co-Chairman and Co-Founder

Ronald S. Lauder  
Co-Chairman and Co-Founder
Dear Friends,

As we celebrate our 25th anniversary year, we could not feel prouder to be at the helm of an organization that has helped lay the path for the future of Alzheimer’s treatments and diagnostics.

From our origins as one of the early adopters of the biology of aging theory, advocating for a broad approach that tackles all the varied causes contributing to this disease, the Alzheimer’s Drug Discovery Foundation (ADDF) has played a fundamental role in influencing the thinking of the field and leading us into the modern era of Alzheimer’s research.

We have witnessed a level of progress never before seen in the Alzheimer’s field this past year, with multiple anti-amyloid drugs emerging on the market. We are proud to say the Amyvid PET scan, which was seed funded by the ADDF, played a critical role in these clinical trials.

Moreover, the ADDF has spent years seeding the pipeline with diverse trials, which have set the stage for us to lead the way in this new era, where prevention methods, combination therapy, and precision medicine will revolutionize treatment.

Representatives from the ADDF have been invited to speak at and shape the agendas of forums around the world in 2023, from the Milken Global Conference in Los Angeles to the Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) in Gothenburg, Sweden to the Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston.

We are honored to leverage these platforms to spotlight the boldest scientific ideas, catalyze further study of the biology of aging, and shepherd research and funding in the right direction so we can get effective treatments into the hands of patients as quickly as possible.

We owe tremendous gratitude to everyone who makes this critical work possible, most especially the Lauder family, who this year gave a historic $200 million gift – inspired by the momentum we have spurred in the field – that will allow us to complete our mission.

Research has reached a critical inflection point and thanks to your support, we are closer than ever to defeating Alzheimer’s.

Many thanks,

Howard Fillit, MD
Co-Founder & Chief Science Officer

Mark Roithmayr
Chief Executive Officer
**Therapeutics**

Advancing Treatments Through Our Signature Focus On Diverse Targets

**Using a 360-Degree View to Seek New Answers**

This year, we have seen significant progress in the field, with breakthroughs for amyloid-targeting drugs like Leqembi and donanemab. At the ADDF, our focus is advancing novel drugs that can be used in combination with anti-amyloids in a precision medicine approach – which has proven successful in cancer treatment – to address the unique causes of each patient’s disease.

We believe every possible cause of Alzheimer’s is worthy of research because each aging-related target presents another potential pathway to a cure. As a result, our portfolio is one of the largest and most diverse in the world.

**Innovative Ideas + Strategic Investments = Impact**

Our venture philanthropy financing model funnels profits from successful investments back into supporting additional research. This enables us to assume risks others cannot and support unique research approaches that have great potential but are in danger of going overlooked or underfunded. The influence of our approach is reflected in today’s clinical trials pipeline, where three quarters of trials are aimed at targets other than amyloid and tau.

---

**OUR PIPELINE AT A GLANCE**

**Active Clinical Trials by Drug Target**

- **18%** Inflammation
- **18%** Synaptic Activity & Neurotransmitters
- **16%** Mitochondria & Metabolic Function
- **16%** Other
- **9%** Misfolded Proteins
- **5%** Biomarkers
- **5%** Cellular Senescence
- **5%** Genetics & Epigenetics
- **5%** Neuroprotection
- **3%** Proteostasis
The Path Toward Effective Treatments Starts With An Early And Accurate Diagnosis

ADDF-Funded Screening Tool Facilitates Milestone Drug Approval

ADDF-supported diagnostics are already making a notable impact, improving clinical trial designs and serving as the driving force behind recent breakthroughs. The Amyvid PET scan—which received early seed funding from the ADDF—is being used to enroll patients and demonstrate target engagement in studies for amyloid-targeting drugs. These include Eisai and Biogen’s Leqembi, which earlier this year became the first ever disease-modifying Alzheimer’s drug to receive full approval from the FDA, as well as Eli Lilly’s donanemab.

In addition, C2N’s PrecivityAD blood test, the development of which was also supported by the ADDF, is available to help physicians with early detection of Alzheimer’s in 49 of 50 U.S. states, requiring as little as a teaspoon of blood.

This progress is driving momentum in the field, paving the way for the next wave of trial design. Researchers will be able to use novel biomarkers to begin conducting combination therapy trials, which will allow us to gain a deeper understanding of how multiple drugs interact with one another as part of a broader treatment strategy for Alzheimer’s.

Doubling Down on Game-Changing Partnerships

The ADDF has recently redoubled our efforts to speed the development of diagnostic tools to detect early subtle changes that signal Alzheimer’s with the launch of the next phase of our Diagnostics Accelerator.

This second phase brings the initiative’s total capital to $100 million, with new funders the NFL Players Association, Eli Lilly & Company, Biogen, and the Shanahan Family Foundation joining our initial funders, who include Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, and the Dolby family, among others.

The projects supported by the Diagnostics Accelerator; which include blood tests, eye scans, and digital technologies like apps; will lay the groundwork for improved trials and the development of the next class of Alzheimer’s drugs.

“If we want to stop Alzheimer’s, one of the biggest things we need to develop is a reliable, affordable, and accessible diagnostic... Many [Diagnostics Accelerator] award recipients are already making terrific progress.”

Bill Gates, Inaugural Funder of the Diagnostics Accelerator
Stopping Disease Progression Before It Starts

First-of-its Kind Partnership Unites World Leaders in Therapeutics and Prevention

This year marked the beginning of a revolutionary new Precision Prevention Partnership between the ADDF and the FINGERS Brain Health Institute (FBHI), which holds the potential to transform the landscape of Alzheimer's prevention and treatment.

The partnership will further accelerate the momentum built by recent breakthroughs in drug and biomarker development by combining the ADDF’s world-class expertise in therapeutics development with the knowledge of the global leader in Alzheimer’s prevention and founder of FBHI, Miia Kivipelto, MD, PhD.

Together, we will bring physicians the tools they need to use patients’ biomarker profiles, combined with their medical and family histories, to tailor drug and lifestyle interventions for maximum effect. These efforts will allow us to lead the way in shaping the future of Alzheimer’s care.

Educating Stakeholders Across the Alzheimer’s Universe

In our role as thought leaders in the Alzheimer’s arena, part of our mission is to evaluate and disseminate information on the latest prevention research. The blogs and ratings on our Cognitive Vitality website are designed to deliver science-backed strategies to help people make smarter lifestyle decisions, promote brain health, and potentially ward off disease.

In addition, our Cognitive Vitality Reports spark the thinking of researchers and physicians with their in-depth evaluations performed by our expert team of in-house neuroscientists. These reports cover drugs, drugs-in-development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors.
Stewardship

Sixth Annual Hope on the Horizon Palm Beach Dinner
1. Bonnie Englebardt Lautenberg, Heidi McWilliams, and Nancy Goodes
2. Leonard A. Lauder, Bonnie Englebardt Lautenberg, and Judy Lauder

Sixth Annual Memories Matter
3. Ian Ginsberg, Stephanie Ginsberg, Wendy Wilshin, and Ron Dickerman
4. Doug Winshall, Wendi Winshall, Hope Altheim, and Marc Altheim
5. Mark Macy, Travis Macy, and Josh Lauder

Thirteenth Annual Great Ladies Luncheon and Fashion Show
6. Marc Lefkowitz, Amy Baier, Elise Lefkowitz, and Mark Roithmayr
7. Kristin Cecchi, Ashley Taylor Bronczek, and Charlie Lefkowitz
Stewardship

Sixteenth Annual
Connoisseur’s Dinner

1. William Lauder, Jane Lauder, Ronald S. Lauder, Aerin Lauder Zinterhofer, and Gary Lauder
2. Mark Rolthmayr, Aerin Lauder Zinterhofer, William Lauder, Jane Lauder, Ronald S. Lauder, Gary Lauder, Paula Zahn, and Howard Fillit
3. Ronald S. Lauder and Paula Zahn

Second Annual
House of Purple

4. Aaron Hoyt, Michelle Florin, Lizzie Toma, and Rick Gargiulo
5. Josh Lauder, Lizzie Toma, and Gina Holzheimer
6. Lizzie Toma